In our study, CCL2 secretion was significantly increased in AML-MSCs compared to D-MSCs both at the onset (Log2FC = 2.4, p = 0.006) and in remission (Log2FC = 2.96, p = 0.0001), but there were no differences in ALL-MSCs. Here, CCL2 is linked to acute myeloid leukemia.